Dilated Cardiomyopathy due to LMNA (Lamin A/C) gene mutations: We are participating in the open-label extension study, A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy. This study was designed to pilot a novel treatment for LMNA-related dilated cardiomyopathy in twelve patients. This trial is still active, but recruitment has closed. More details available at: ClinicalTrials.gov (Study Number: NCT02351856)
Hypertrophic Cardiomyopathy: We are participating in the ongoing VANISH (Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM) trial that is treating patients with early-stage Hypertrophic Cardiomyopathy (HCM) with specific genetic mutations. This trial is still active, but recruitment has closed. More details available at: ClinicalTrials.gov (Study Number: NCT01912534)
Registry Trials:
Our ongoing disease registry trials remain active and include recruitment for patients with:
Familial Dilated Cardiomyopathy Registry: Enrolling patients and families with
Danon Disease Registry: Enrolling patients and families with
Lysosomal Storage Disease Registry: Enrolling patients and families with
LMNA Disease Registry: Enrolling patients and families with LMNA (Lamin A/C) related genetic cardiomyopathy
Rare-Disease / Mystery-Diagnosis Registry: We are always interested in hearing from patients and families with rare or unusual (so called ‘mystery diagnoses’)
Matthew R. G. Taylor MD, PhD
Director, Adult Clinical Genetics
303-724-1400 (office)
720-848-0469 (fax)
720-848-0782(appointments)
matthew.taylor@ucdenver.edu